CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024 11:23 ET
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024 10:00 ET
|
CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01
December 06, 2023 07:00 ET
|
Ractigen Therapeutics
This milestone marks Ractigen's transition into clinical development, with RAG-01 targeting NMIBC.
Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners
September 27, 2023 10:12 ET
|
The Insight Partners
Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...
Non-Muscle Invasive Bladder Cancer Market is Expected to Showcase Significant Growth, Predicts DelveInsight | Key Companies in the Space - Protara, Janssen, Tyra, Pfizer, Roche, CG Oncology, ImmunityBio, Theralase, enGene, SURGE
June 08, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, June 08, 2023 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Market is Expected to Showcase Significant Growth, Predicts DelveInsight | Key Companies in the Space - Protara,...
Theralase® Releases FY2022 Audited Financial Statements
April 26, 2023 18:01 ET
|
Theralase Technologies Inc.
TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium
February 23, 2023 07:00 ET
|
Theralase Technologies Inc.
TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase Expands Intellectual Property Portfolio
June 28, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Research - One of the Top 10 Most Downloaded Papers
June 24, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...